301 related articles for article (PubMed ID: 26587888)
1. Molecular Imaging of Prostate Cancer.
Wibmer AG; Burger IA; Sala E; Hricak H; Weber WA; Vargas HA
Radiographics; 2016; 36(1):142-59. PubMed ID: 26587888
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Prostate Cancer with Radiolabeled Amino Acid Analogs.
Schuster DM; Nanni C; Fanti S
J Nucl Med; 2016 Oct; 57(Suppl 3):61S-66S. PubMed ID: 27694174
[TBL] [Abstract][Full Text] [Related]
3. Molecular imaging of prostate cancer with PET.
Jadvar H
J Nucl Med; 2013 Oct; 54(10):1685-8. PubMed ID: 24084704
[TBL] [Abstract][Full Text] [Related]
4. Bombesin-Targeted PET of Prostate Cancer.
Mansi R; Minamimoto R; Mäcke H; Iagaru AH
J Nucl Med; 2016 Oct; 57(Suppl 3):67S-72S. PubMed ID: 27694175
[TBL] [Abstract][Full Text] [Related]
5. Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist.
Zhang H; Desai P; Koike Y; Houghton J; Carlin S; Tandon N; Touijer K; Weber WA
J Nucl Med; 2017 Jan; 58(1):29-35. PubMed ID: 27516447
[TBL] [Abstract][Full Text] [Related]
6. Exploitation of CD133 for the Targeted Imaging of Lethal Prostate Cancer.
Glumac PM; Gallant JP; Shapovalova M; Li Y; Murugan P; Gupta S; Coleman IM; Nelson PS; Dehm SM; LeBeau AM
Clin Cancer Res; 2020 Mar; 26(5):1054-1064. PubMed ID: 31732520
[TBL] [Abstract][Full Text] [Related]
7. Clinical PET Imaging in Prostate Cancer.
Wallitt KL; Khan SR; Dubash S; Tam HH; Khan S; Barwick TD
Radiographics; 2017; 37(5):1512-1536. PubMed ID: 28800286
[TBL] [Abstract][Full Text] [Related]
8. PET Tracers Beyond FDG in Prostate Cancer.
Schuster DM; Nanni C; Fanti S
Semin Nucl Med; 2016 Nov; 46(6):507-521. PubMed ID: 27825431
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and radiopharmacological evaluation of a high-affinity and metabolically stabilized 18F-labeled bombesin analogue for molecular imaging of gastrin-releasing peptide receptor-expressing prostate cancer.
Richter S; Wuest M; Krieger SS; Rogers BE; Friebe M; Bergmann R; Wuest F
Nucl Med Biol; 2013 Nov; 40(8):1025-34. PubMed ID: 23969085
[TBL] [Abstract][Full Text] [Related]
10. Targeted PET imaging for prostate-specific membrane antigen in prostate cancer.
Hope TA; Aggarwal RR; Westphalen AC; Cooperberg MR; Greene KL
Future Oncol; 2016 Nov; 12(21):2393-2396. PubMed ID: 27453303
[No Abstract] [Full Text] [Related]
11. PET of Glucose Metabolism and Cellular Proliferation in Prostate Cancer.
Jadvar H
J Nucl Med; 2016 Oct; 57(Suppl 3):25S-29S. PubMed ID: 27694167
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Castration-Resistant Prostate Cancer with Androgen Receptor-Axis Imaging.
Pandit-Taskar N; Veach DR; Fox JJ; Scher HI; Morris MJ; Larson SM
J Nucl Med; 2016 Oct; 57(Suppl 3):73S-78S. PubMed ID: 27694177
[TBL] [Abstract][Full Text] [Related]
13. Uptake of the prostate-specific membrane antigen-targeted PET radiotracer 18F-DCFPyL in elastofibroma dorsi.
Gorin MA; Marashdeh W; Ross AE; Allaf ME; Pienta KJ; Pomper MG; Rowe SP
Nucl Med Commun; 2017 Sep; 38(9):795-798. PubMed ID: 28704341
[TBL] [Abstract][Full Text] [Related]
14. New aspects of molecular imaging in prostate cancer.
Ceci F; Castellucci P; Cerci JJ; Fanti S
Methods; 2017 Nov; 130():36-41. PubMed ID: 28711565
[TBL] [Abstract][Full Text] [Related]
15. microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts.
Chen X; Park R; Hou Y; Tohme M; Shahinian AH; Bading JR; Conti PS
J Nucl Med; 2004 Aug; 45(8):1390-7. PubMed ID: 15299066
[TBL] [Abstract][Full Text] [Related]
16. Clinical Applications of Molecular Imaging in the Management of Prostate Cancer.
Gorin MA; Rowe SP; Denmeade SR
PET Clin; 2017 Apr; 12(2):185-192. PubMed ID: 28267452
[TBL] [Abstract][Full Text] [Related]
17. A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer.
Pandit-Taskar N; O'Donoghue JA; Durack JC; Lyashchenko SK; Cheal SM; Beylergil V; Lefkowitz RA; Carrasquillo JA; Martinez DF; Fung AM; Solomon SB; Gönen M; Heller G; Loda M; Nanus DM; Tagawa ST; Feldman JL; Osborne JR; Lewis JS; Reuter VE; Weber WA; Bander NH; Scher HI; Larson SM; Morris MJ
Clin Cancer Res; 2015 Dec; 21(23):5277-85. PubMed ID: 26175541
[TBL] [Abstract][Full Text] [Related]
18. Molecular imaging of prostate cancer.
Emonds KM; Swinnen JV; Mortelmans L; Mottaghy FM
Methods; 2009 Jun; 48(2):193-9. PubMed ID: 19362147
[TBL] [Abstract][Full Text] [Related]
19. Current use of PSMA-PET in prostate cancer management.
Maurer T; Eiber M; Schwaiger M; Gschwend JE
Nat Rev Urol; 2016 Apr; 13(4):226-35. PubMed ID: 26902337
[TBL] [Abstract][Full Text] [Related]
20. Cerenkov Luminescence Imaging as a Modality to Evaluate Antibody-Based PET Radiotracers.
D'Souza JW; Hensley H; Doss M; Beigarten C; Torgov M; Olafsen T; Yu JQ; Robinson MK
J Nucl Med; 2017 Jan; 58(1):175-180. PubMed ID: 27539844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
